The deal is a bet on the growing market for psychiatric and neurological drugs.
Read More Bristol Myers Squibb Company, Karuna Therapeutics Inc, Drugs (Pharmaceuticals), Mergers, Acquisitions and Divestitures, Mental Health and Disorders, Food and Drug Administration
